Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

Combining Neprilysin Inhibitor With AT2R Agonist Is Superior to Combination With AT1R Blocker in Providing Reno-Protection in Obese Rats

Frontiers in Pharmacology(2022)10.3389/fphar.2021.778953Source: DataRank Database

Combining Neprilysin Inhibitor With AT2R Agonist Is Superior to Combination With AT1R Blocker in Providing Reno-Protection in Obese Rats is a research paper published in Frontiers in Pharmacology (2022). On theSindex it has a DataRank of 0. It has been cited 3 times.

N/A

0DataRank · unranked

Scored on demand from live citation data

Open Access3 citations

Download PDF

Cite:

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (4 grants)Impact (FWCI 0.46)OA: goldTopics (29)IDs (PubMed, PMC, OpenAlex)SDGs (3)

FAIR Checklist

Context only (not used in score)

Findable (1/2)

Has DOI

Accessible (1/2)

Open Access

Interoperable (0/2)

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

Authors (4)

Sanket Patel ORCID,Peter A. Doris ORCID,Tahir Hussain ORCID,Elizabeth A. Gray

Live enrichment

PubMed:35197849 PMC:PMC8859315 OpenAlex:https://openalex.org/W4210269287

National Institutes of Health

Grant: 1R01DK117495-01

Protective Arm of the Renin Angiotensin System in Obese Kidney

National Institutes of Health

Grant: 5F31DK122740-02

Reno-protection afforded by combinatory approach targeting AT2R and neprilysin in obesity

National Institutes of Health

Grant: 1R01DK061578-01A1

Renal Angiotensin ll Receptor Function in Obesity

National Institute of Diabetes and Digestive and Kidney Diseases

FWCI

0.46

Citation Percentile

0.6%

Citation Trend

2023

2025

goldLicense: cc-by

journalhttps://doi.org/10.3389/fphar.2021.778953

publisherhttps://doi.org/10.3389/fphar.2021.778953

publisherhttps://www.frontiersin.org/articles/10.3389/fphar.2021.778953/full

repositoryhttps://pubmed.ncbi.nlm.nih.gov/35197849

repositoryhttps://doaj.org/article/b708b8b3effd43adb6548d8bfa46f871

Fields of Study

Renin-Angiotensin System StudiesBlood Pressure and Hypertension StudiesHormonal Regulation and Hypertension0301 basic medicine0303 health sciences03 medical and health sciences0302 clinical medicine

Keywords

SacubitrilValsartanAlbuminuriaSacubitril, ValsartanInternal medicineEndocrinologyMedicineProteinuriaRenal functionNeprilysinCreatinineKidneyChemistryBlood pressureObesityAngiotensin Receptor BlockerNeprilysin InhibitionReno-protectionAngiotensin Ii Type 2 Receptor AgonistPharmacologyRM1-950Therapeutics. Pharmacology

Sustainable Development Goals

SDG 2: 2. Zero hungerSDG 3: 3. Good healthSDG 0: Good health and well-being